Mirum Pharmaceuticals, Inc.
MIRM
Kedudukan dalam Saham
#3271
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Harga Saham
$82.73
Modal Pasaran
$5.37B
Perubahan (1 hari)
0.60%
Perubahan (1 tahun)
13.28%
Negara
US
Perdagangan Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
Bilangan saham terbitan bagi Mirum Pharmaceuticals, Inc. (MIRM)
Bilangan saham terbitan setakat June 2026: 63.37M
Menurut laporan kewangan terkini dan harga saham Mirum Pharmaceuticals, Inc., bilangan saham terbitan semasa ialah 63.37M. Pada akhir December 2023, syarikat mempunyai 40.89M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Mirum Pharmaceuticals, Inc. (MIRM) dari 2018 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 63.37M | 33.35% |
| 2024 | 47.52M | 16.24% |
| 2023 | 40.89M | 20.82% |
| 2022 | 33.84M | 11.60% |
| 2021 | 30.32M | 20.08% |
| 2020 | 25.25M | 9.84% |
| 2019 | 22.99M | 0.00% |
| 2018 | 22.99M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 300.64% |
US
|
|
| 396.00M | 524.86% |
US
|
|
| 478.91M | 655.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -1.88% |
NL
|
